Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
United States, Canada144 participantsStarted 2022-05-26
Plain-language summary
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock.
This study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited.
The study aims to answer the question: "Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?"
The study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants or substitute decision maker is able and willing to provide written informed consent
✓. Age ≥ 18 years
✓. SCAI stage C or D cardiogenic shock with persistent inotrope/vasopressor/non-durable mechanical support or unable to wean ventilatory support due to pulmonary edema for 24 hours prior to randomization
✓. Greater than or equal to 3+ MR as determined by a study center's transesophageal echocardiogram (TEE)
✓. In the opinion of the study center's heart team the participant is anatomically eligible for TMVr with the potential to achieve \<3+ MR
Exclusion criteria
✕. Unwilling or unable to obtain informed consent from the participant or substitute decision maker
✕. Revascularization of coronary artery disease performed in the 48 hours prior to randomization
✕. If the mechanism of MR is deemed to be degenerative, in the opinion of the heart team the participant is eligible for surgical intervention
What they're measuring
1
Primary composite outcome
Timeframe: Through duration of hospitalization, generally up to 12 weeks following admission
Trial details
NCT IDNCT05298124
SponsorOttawa Heart Institute Research Corporation
. Prior mitral valve leaflet surgery or implanted mitral valve prosthesis (excluding ring)
✕. Echocardiographic evidence of left sided intracardiac mass or thrombus
✕. Diagnosis of active infective endocarditis
✕. Transesophageal echocardiogram is contraindicated
✕. Mitral valve anatomy deemed contraindication to TMVr implantation that cannot be addressed procedurally as determined by the study center's heart team